Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. ADR (NQ: CLLS )

3.680 -0.300 (-7.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,162
Open 3.900
Bid (Size) 3.360 (1)
Ask (Size) 3.810 (7)
Prev. Close 3.980
Today's Range 3.680 - 3.900
52wk Range 2.300 - 15.50
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga

Performance

YTD
-58.04%
-58.04%
1 Month
+41.00%
+41.00%
3 Month
+12.54%
+12.54%
6 Month
-34.40%
-34.40%
1 Year
-70.15%
-70.15%

More News

Read More
Cellectis Gets FDA Nod For Initial-Stage Non-Hodgkin Lymphoma Study
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
Via Benzinga
Recap: Cellectis Q4 Earnings
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut
Via Benzinga
Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma
Via Benzinga
A Preview Of Cellectis's Earnings
Via Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Earnings Scheduled For March 3, 2022
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
FDA Lifts Clinical Hold On Allogene's CAR-T Trials
Via Benzinga
21 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.